Annalisa D’Andrea
Director/Board Member presso Engimmune Therapeutics AG
Profilo
Annalisa D’Andrea is currently a Non-Executive Director at Engimmune Therapeutics AG and a Venture Partner at Longwood Fund Management LLC.
Previously, she held positions as an Executive Director & Head-Discovery Biology at SRI International, Vice President & Global Head-Discovery at Roche Holding AG, Chief Scientific Officer at Kiniksa Pharmaceuticals Ltd., and President & Chief Scientific Officer at ImmuneID, Inc. Ms. D’Andrea obtained a doctorate degree from the University of Florence and an undergraduate degree from the University of Siena.
Posizioni attive di Annalisa D’Andrea
Società | Posizione | Inizio |
---|---|---|
Engimmune Therapeutics AG
Engimmune Therapeutics AG Packaged SoftwareTechnology Services Engimmune Therapeutics AG is a developer of off-the-shelf soluble T-cell receptor drugs to treat solid tumors. The company is based in Allschwil, Switzerland. The Swiss company's proprietary platform technologies enable them to engineer stable, multi-specific TCRs that have high affinity for target cancer antigens and trigger a potent and durable anti-cancer T-cell response without causing damage to healthy cells. The company was founded in 2021 as a spin-off of ETH Zurich from technologies developed by Dr. Rodrigo Vazquez-Lombardi and Professor Sai Reddy. Lars Nieba has been the CEO of the company since 2023. | Director/Board Member | 24/05/2023 |
Longwood Fund Management LLC
Longwood Fund Management LLC Investment ManagersFinance Longwood Fund Management LLC (Longwood Fund Management) is a venture capital firm founded in 2010 by Christoph H. Westphal, Michelle Dipp and Richard H. Aldrich. The firm is headquartered in Boston, Massachusetts. | Private Equity Investor | - |
Precedenti posizioni note di Annalisa D’Andrea
Società | Posizione | Fine |
---|---|---|
ImmuneID, Inc.
ImmuneID, Inc. Miscellaneous Commercial ServicesCommercial Services ImmuneID, Inc. is a precision immunology company that combines next-generation sequencing with protein display technologies to develop novel therapies for immune diseases. The company's proprietary platform identifies millions of antibody-target interactions to build the map of human immunity, which helps to improve and personalize patient diagnoses for precise treatments. The company was founded in 2020 by Longwood Fund and is headquartered in Boston, MA. James S. Scibetta has been the CEO of the company since 2021. | President | - |
ROCHE HOLDING AG | Corporate Officer/Principal | - |
SRI International
SRI International Miscellaneous Commercial ServicesCommercial Services SRI International provides contract research and development services. It is an independent, nonprofit research institute conducting client-sponsored research and development for government agencies, commercial businesses, foundations, and other organizations. The company was founded in 1946 and is headquartered in Menlo Park, CA. | Director/Board Member | - |
KINIKSA PHARMACEUTICALS, LTD. | Chief Tech/Sci/R&D Officer | - |
Formazione di Annalisa D’Andrea
University of Florence | Doctorate Degree |
University of Siena | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
ROCHE HOLDING AG | Health Technology |
KINIKSA PHARMACEUTICALS, LTD. | Health Technology |
Aziende private | 4 |
---|---|
SRI International
SRI International Miscellaneous Commercial ServicesCommercial Services SRI International provides contract research and development services. It is an independent, nonprofit research institute conducting client-sponsored research and development for government agencies, commercial businesses, foundations, and other organizations. The company was founded in 1946 and is headquartered in Menlo Park, CA. | Commercial Services |
Longwood Fund Management LLC
Longwood Fund Management LLC Investment ManagersFinance Longwood Fund Management LLC (Longwood Fund Management) is a venture capital firm founded in 2010 by Christoph H. Westphal, Michelle Dipp and Richard H. Aldrich. The firm is headquartered in Boston, Massachusetts. | Finance |
ImmuneID, Inc.
ImmuneID, Inc. Miscellaneous Commercial ServicesCommercial Services ImmuneID, Inc. is a precision immunology company that combines next-generation sequencing with protein display technologies to develop novel therapies for immune diseases. The company's proprietary platform identifies millions of antibody-target interactions to build the map of human immunity, which helps to improve and personalize patient diagnoses for precise treatments. The company was founded in 2020 by Longwood Fund and is headquartered in Boston, MA. James S. Scibetta has been the CEO of the company since 2021. | Commercial Services |
Engimmune Therapeutics AG
Engimmune Therapeutics AG Packaged SoftwareTechnology Services Engimmune Therapeutics AG is a developer of off-the-shelf soluble T-cell receptor drugs to treat solid tumors. The company is based in Allschwil, Switzerland. The Swiss company's proprietary platform technologies enable them to engineer stable, multi-specific TCRs that have high affinity for target cancer antigens and trigger a potent and durable anti-cancer T-cell response without causing damage to healthy cells. The company was founded in 2021 as a spin-off of ETH Zurich from technologies developed by Dr. Rodrigo Vazquez-Lombardi and Professor Sai Reddy. Lars Nieba has been the CEO of the company since 2023. | Technology Services |
- Borsa valori
- Insiders
- Annalisa D’Andrea